Literature DB >> 28751038

Small hepatocellular carcinomas displayed as a ring enhancing mass on arterial phase MRI in the chronically diseased liver.

R H Jones1, A J Taylor2, N Rostambeigi1, B Spilseth1.   

Abstract

AIM: To assess the prevalence of arterial phase (AP) ring-enhancing small hepatocellular carcinomas (HCC) on magnetic resonance imaging (MRI); detail additional MRI features that enable HCC diagnosis; and examine arterial timing as one possible cause of this appearance.
MATERIALS AND METHODS: Patients undergoing HCC screening with both computed tomography (CT) and MRI within 40 days were examined at a single institution over a 7- year time period ending in 2013. From this initial group, small (1-3 cm), (AP) ring-enhancing HCC on MRI were studied.
RESULTS: From the initial group of 64 patients with 129 HCC, 20 patients with 78 HCCs had a small diameter with 32 (41%) having an AP ring at MRI. The mean age of this latter group was 63-years old, with the average tumour diameter of 1.9 cm. Histopathology and secondary imaging supported a diagnosis of HCC in 20 (100%) patients and 31 (97%) lesions. Most of the ringed lesions had early AP timing.
CONCLUSION: This study revealed a high prevalence (41%) of small, AP ring HCC with MRI. The use of other MRI sequences adds support in making the proper diagnosis with this appearance. Early AP timing may help create this pattern.
Copyright © 2017 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28751038     DOI: 10.1016/j.crad.2017.07.001

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  1 in total

1.  The Role of Preoperative Dynamic Contrast-enhanced 3.0-T MR Imaging in Predicting Early Recurrence in Patients With Early-Stage Hepatocellular Carcinomas After Curative Resection.

Authors:  Linqi Zhang; Sichi Kuang; Jingbiao Chen; Yao Zhang; Binliang Zhao; Hao Peng; Yuanqiang Xiao; Kathryn Fowler; Jin Wang; Claude B Sirlin
Journal:  Front Oncol       Date:  2019-11-28       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.